公开(公告)号：US20240287194A1

公开(公告)日：2024-08-29

申请号：US18289836

申请日：2022-05-13

申请人： The General Hospital Corporation

发明人： Shadmehr Demehri

IPC分类号： C07K16/28 ,  A61K31/192 ,  A61K31/4178 ,  A61K39/00 ,  A61P35/00

CPC分类号： C07K16/2848 ,  A61K31/192 ,  A61K31/4178 ,  A61P35/00 ,  C07K16/2803 ,  C07K16/2842 ,  A61K2039/505 ,  C07K2317/76

摘要： Elucidating the mechanism that underlies tissue-specific NK cell responses will have major implications in cancer immunology, transplant biology and virology. Provided herein are compositions and methods for of treating a subject who has a solid tumor or who has a viral infection, or promoting cytotoxicity of natural killer (NK) cells in a subject, using (i) blocking antibodies to ECM components and/or (ii) inhibitors of collagen deposition or production.

公开(公告)号：US20240158510A1

公开(公告)日：2024-05-16

申请号：US18549837

申请日：2022-03-08

申请人： The Governing Council of the University of Toronto

发明人： Sachdev S. SIDHU ,  Eugenio GALLO ,  Jarrett J. ADAMS ,  Levi Lynn BLAZER ,  Rodilia CARDARELLI ,  Abdellali KELIL

IPC分类号： C07K16/28 ,  A61P35/00

CPC分类号： C07K16/2842 ,  A61P35/00 ,  C07K16/2818 ,  C07K2317/31 ,  C07K2317/76

摘要： The disclosure provides antibodies that bind human ITGAv/B1 and methods of use thereof. In some aspects, the disclosure is directed to methods of treating a cancer in a subject, comprising administering to the subject an anti-ITGAv/B1 antibody.

公开(公告)号：US20240069017A1

公开(公告)日：2024-02-29

申请号：US18493294

申请日：2023-10-24

申请人： Paul Viktor Lehmann

发明人： Paul Viktor Lehmann

IPC分类号： G01N33/564 ,  A61K31/136 ,  A61K31/137 ,  A61K31/785 ,  A61K38/21 ,  A61P37/06 ,  C07K16/28 ,  C12N5/0781

CPC分类号： G01N33/564 ,  A61K31/136 ,  A61K31/137 ,  A61K31/785 ,  A61K38/215 ,  A61P37/06 ,  C07K16/2842 ,  C07K16/2887 ,  C12N5/0635 ,  C07K2317/24 ,  C12N2503/00

摘要： Embodiments of this disclosure include methods for detecting autoimmune diseases by detecting the presence of autoantibodies directed against self-antigens (or “respective antoantigens”). In particular, embodiments of this disclosure include detecting autoantibodies produced by B cells from a patient suspected of having an autoimmune disease using a Direct B Cell test. Other embodiments include detecting autoantibodies produced by memory B cells using a Memory B Cell test. Further embodiments include methods of treatment of a patient having an autoimmune disease comprising administering a substance that decreases B cell numbers. Other embodiments comprise treating a patient with other known treatments.

公开(公告)号：US11903960B2

公开(公告)日：2024-02-20

申请号：US17645762

申请日：2021-12-23

申请人： The Brigham and Women's Hospital, Inc.

发明人： Vishal S. Vaidya ,  Casimiro Gerarduzzi

IPC分类号： C07H21/04 ,  A61K31/712 ,  A61P13/12 ,  C07K16/28 ,  C12N15/113 ,  C07K16/18 ,  A61P43/00

CPC分类号： A61K31/712 ,  A61P13/12 ,  A61P43/00 ,  C07K16/18 ,  C07K16/2842 ,  C12N15/113 ,  C07K2317/76 ,  C12N2310/14

摘要： Described herein are methods for treating fibrosis, e.g., kidney fibrosis, using agents that target Secreted Modular Calcium-binding protein 2 (SMOC2).

公开(公告)号：US11806382B2

公开(公告)日：2023-11-07

申请号：US16951650

申请日：2020-11-18

申请人： UNIVERSITY OF IOWA RESEARCH FOUNDATION

发明人： Anil K. Chauhan ,  Nirav A. Dhanesha

IPC分类号： A61K38/10 ,  A61K38/39 ,  A61P9/10 ,  A61K38/18 ,  A61K38/17 ,  A61K38/19 ,  A61K39/395 ,  A61P29/00 ,  C07K16/28 ,  A61K39/00 ,  A61K9/00 ,  C07K14/47 ,  C07K7/08 ,  C07K14/78 ,  C07K14/46 ,  C07K14/705 ,  C07K14/52

CPC分类号： A61K38/10 ,  A61K38/1703 ,  A61K38/1709 ,  A61K38/1774 ,  A61K38/1866 ,  A61K38/19 ,  A61K38/39 ,  A61K39/3955 ,  A61P9/10 ,  A61P29/00 ,  A61K9/0019 ,  A61K2039/505 ,  A61K2039/54 ,  C07K7/08 ,  C07K14/46 ,  C07K14/47 ,  C07K14/4703 ,  C07K14/52 ,  C07K14/70503 ,  C07K14/78 ,  C07K16/2842 ,  C07K2317/76

摘要： The invention provides a method and kits for inhibiting integrin α9β1 activity comprising contacting integrin α9β1 or a binding partner of integrin α9β1 with an isolated anti-integrin α9 inhibitor, wherein the integrin α9β1 activity is inhibited. In certain aspects, the present invention provides a novel intervention by targeting integrin α9β1 with a functional blocking inhibitor (e.g., peptides or antibodies) to limit brain damage following reperfusion after ischemic stroke.

公开(公告)号：US20190218299A1

公开(公告)日：2019-07-18

申请号：US16302582

申请日：2017-05-19

申请人： MOMENTA PHARMACEUTICALS, INC.

发明人： Joel PRADINES ,  Elma KURTAGIC

IPC分类号： C07K16/28

CPC分类号： C07K16/2842 ,  A61K38/00 ,  C07K16/2839 ,  C07K2317/24

摘要： Provided herein are methods for treating fibrosis, including diseases or disorders associated with fibrosis, for example systemic sclerosis.

公开(公告)号：US20190137511A1

公开(公告)日：2019-05-09

申请号：US16115350

申请日：2018-08-28

申请人： BIOGEN MA INC.

发明人： Gary Lewis BLOOMGREN ,  Carmen BOZIC ,  Sophia LEE ,  Amy PACE ,  Tatiana PLAVINA ,  Meena SUBRAMANYAM

IPC分类号： G01N33/68 ,  C07K16/28 ,  G01N33/569 ,  C12N7/00

CPC分类号： G01N33/6854 ,  C07K16/2842 ,  C07K2317/24 ,  C12N7/00 ,  C12N2710/22011 ,  C12Q1/70 ,  G01N33/56983 ,  G01N2333/025 ,  G01N2469/20 ,  G01N2800/24 ,  G01N2800/28 ,  G01N2800/50

摘要： The invention relates to methods of assessing a patient's risk of developing Progressive multifocal leukoencephalopathy (PML).

公开(公告)号：US20180369215A1

公开(公告)日：2018-12-27

申请号：US16020696

申请日：2018-06-27

申请人： BIOGEN MA INC.

发明人： Jermaine Thomas ,  Sha Mi ,  Edward Yin-Shiang Lin ,  Guo Zhu Zheng ,  Bin Ma ,  Richard D. Caldwell ,  Kevin M. Guckian ,  Gnanasambandam Kumaravel

IPC分类号： A61K31/445 ,  A61K31/517 ,  C07D211/34 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/498 ,  A61K31/55 ,  A61K31/225 ,  A61K31/695 ,  C07K16/28 ,  A61K38/21 ,  A61K39/395 ,  C07D215/20 ,  C07D405/12 ,  C07D401/06 ,  C07D211/62 ,  C07D211/60

CPC分类号： A61K31/445 ,  A61K31/225 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/498 ,  A61K31/517 ,  A61K31/55 ,  A61K31/695 ,  A61K38/21 ,  A61K39/3955 ,  C07D211/34 ,  C07D211/60 ,  C07D211/62 ,  C07D215/20 ,  C07D401/06 ,  C07D405/12 ,  C07K16/2842

摘要： Compounds of formula (I) or (II) can modulate the activity of S1P receptors.

公开(公告)号：US20180312591A1

公开(公告)日：2018-11-01

申请号：US16033875

申请日：2018-07-12

申请人： OncoSynergy, Inc.

发明人： W. Shawn Carbonell

IPC分类号： C07K16/28 ,  A61K49/00 ,  G01N33/574 ,  A61K47/68 ,  A61K39/00

CPC分类号： C07K16/2842 ,  A61K47/6803 ,  A61K49/0004 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/70 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/57484 ,  G01N2333/7055

摘要： The current invention provides human variable chain framework regions and humanized antibodies comprising the framework regions, the antibodies being specific for integrin β1. The invention also provides methods for utilizing the antibodies, for example to treat diseases such as cancer.

公开(公告)号：US20180236073A1

公开(公告)日：2018-08-23

申请号：US15869970

申请日：2018-01-12

申请人： The Regents of the University of California

发明人： Warren Shawn Carbonell ,  Manish Kumar Aghi

IPC分类号： A61K39/395 ,  C07K16/28 ,  A61K49/00 ,  C07K16/22 ,  A61K39/00

CPC分类号： A61K39/39558 ,  A61K49/00 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  C07K16/22 ,  C07K16/2842 ,  C07K2317/73 ,  C12N2740/15043

摘要： Described here are methods and compositions for treating tumors and metastases that improve anti-angiogenesis therapy. By inhibiting these mechanisms in a biological system with an anti-beta one integrin composition in combination with an antiangiogenic composition, tumors and metastases may be deprived of an adequate blood supply, thereby resulting in tumor cell growth arrest and possibly regression, including tumor cell death. The present compositions comprise an anti-beta one integrin agent in combination with an anti-VEGF agent, in a pharmaceutical composition or compositions. Methods of treatment and of imaging are also described.